here is a FDA ' Briefing document - on USING HUMAN CANCEROUS TUMORS' FOR VACCINE MANUFACTURE' ( THEY discuss 3 in...

Originally shared by countessarcadius Ty

here is a FDA ' Briefing document - on USING HUMAN CANCEROUS TUMORS' FOR VACCINE MANUFACTURE' ( THEY discuss 3 in this, ( I have the minutes' to that meeting as well) using' 3 different kinds( they' use more) LUNG , CERVICAL ' AND LYMPHOMA CANCEROUS TUMORS' - then... I ask for people to go and look at many of the' vaccine inserts' and see them say' THEY DON'T TEST' for ' carcinogenic, mutagenic, and impairment of fertility?! - ' with all the ' cancer' and infertility it ' really ' shocked me to see' THEY'VE never' TESTED many of the' vaccines for ' something such as ' causing cancer, ( tumors etc) or impairment of fertility, ( consider how some couples are spending tens of thousands of dollars ' trying' to get pregnant) ( THEY ' discuss' in this document) ( THE FDA)( also admitting before it even starts that ' THERE ARE PEOPLE THERE ( PROFESSIONALS) DISCUSSING THESE ISSUES' AND THERE IS A ' conflict of interest' WELL' that probably means anyone ' ADVOCATING FOR IT' is a part of the bloody vaccine industry'( HAVING FINANCIAL INTEREST!!!!!!!!!!!!!!) ANd be a conflict of interest for them to be at the FDA MEETING AND HAVE A SAY ABOUT ' ANYTHING' IF THE FDA WILL BE BIASED IN THEIR Research on the subject)( so they are admitting right from the start that IT'S PEOPLE WILL FINANCIAL INTEREEST IN THE VACCINE INDUSTRY ' AT FDA MEETINGS' PROMOTING AND ADVOCATING' FOR ' THE GOODNESS OF VACCINES' that are being made with ' HUMAN CANCEROUS TUMORS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Tumorigenic Cells and Cells Derived from 88 Human Tumors; DNA as a Potential Risk Factor, Keith Peden, Ph.D., Chief, LDNAV, DVP/OVRR/CBER https://www.scribd.com/doc/246682536/FDA-Meeting-Human-Tumors-for-Vaccine-Manufacture--------------------------------------------------------ADMITTING

  OUTRIGHT HERE' look    **Residual   DNA   in   vaccines   derived   from tumorigenic cells,   including  those   transformed  by   Ad5,  can   pose  potential  r isks   to   the vaccine    recipient   in   two r  spects:   oncogenicity   and   infectivity.    Each  of    these    biological properties    must    be    considered   and    evaluated  for  each   cell    substrate.**"Designer" Cells   as   Substratesfor the Manufacture  of  Viral   Vaccines -   http://www.fda.gov/ohrms/dockets/ac/01/briefing/3750b1_01.htmI

HAVE MORE HAVE TO FIND IT'


and then even says this!  LOOK   -     The second biological activity of DNA that should be considered is its potential infectivity. If a genome of a DNA virus or the provirus of a retrovirus is present in the cell substrate used for vaccine manufacture, then the residual DNA has the potential, upon inoculation into the vaccine recipient, to produce infectious virus from this DNA and thus establish a productive infection.
 and then even says this!  LOOK   -     The second biological activity of DNA that should be considered is its potential infectivity. If a genome of a DNA virus or the provirus of a retrovirus is present in the cell substrate used for vaccine manufacture, then the residual DNA has the potential, upon inoculation into the vaccine recipient, to produce infectious virus from this DNA and thus establish a productive infection.
https://www.youtube.com/watch?v=XOZM4BY0GM8&feature=share